MX370957B - Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica. - Google Patents
Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica.Info
- Publication number
- MX370957B MX370957B MX2016006927A MX2016006927A MX370957B MX 370957 B MX370957 B MX 370957B MX 2016006927 A MX2016006927 A MX 2016006927A MX 2016006927 A MX2016006927 A MX 2016006927A MX 370957 B MX370957 B MX 370957B
- Authority
- MX
- Mexico
- Prior art keywords
- family
- compound
- prevention
- treatment
- atopic dermatitis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000005660 Abamectin Substances 0.000 title abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 title abstract 2
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 title abstract 2
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 abstract 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960002418 ivermectin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende un compuesto de la familia de avermectina, preferentemente ivermectina, o un compuesto de la familia de milbemicina en un vehículo farmacéuticamente aceptable, para su uso en el tratamiento y/o la prevención de la dermatitis atópica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306633 | 2013-11-29 | ||
PCT/EP2014/075927 WO2015079016A1 (en) | 2013-11-29 | 2014-11-28 | Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016006927A MX2016006927A (es) | 2016-10-28 |
MX370957B true MX370957B (es) | 2020-01-09 |
Family
ID=49713042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006927A MX370957B (es) | 2013-11-29 | 2014-11-28 | Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20170000812A1 (es) |
EP (1) | EP3074021B1 (es) |
JP (2) | JP6448641B2 (es) |
KR (1) | KR102341441B1 (es) |
CN (1) | CN105916511A (es) |
AU (1) | AU2014356444B2 (es) |
CA (1) | CA2930909A1 (es) |
MX (1) | MX370957B (es) |
RU (1) | RU2669942C1 (es) |
WO (1) | WO2015079016A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018083196A1 (en) * | 2016-11-03 | 2018-05-11 | Nestlé Skin Health Sa | Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema |
WO2020021670A1 (ja) * | 2018-07-26 | 2020-01-30 | マルホ株式会社 | 液状外用剤 |
WO2020161771A1 (ja) * | 2019-02-04 | 2020-08-13 | マルホ株式会社 | 皮膚用組成物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0820525B2 (ja) | 1986-12-01 | 1996-03-04 | 防衛庁技術研究本部長 | 磁気補償装置 |
US6399651B1 (en) * | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
JP2004168763A (ja) | 2002-10-30 | 2004-06-17 | Dsr Corp | 皮膚化粧料 |
FR2854074B1 (fr) | 2003-04-24 | 2007-11-23 | Galderma Res & Dev | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques |
PL1620113T3 (pl) | 2003-04-24 | 2011-10-31 | Galderma Sa | Formulacja iwermektyny do stosowania miejscowego do leczenia schorzeń dermatologicznych |
TW200533333A (en) | 2004-02-17 | 2005-10-16 | Otsuka Pharma Co Ltd | Human beta-defensin production accelerator |
DE602005020912D1 (de) | 2004-03-18 | 2010-06-10 | Galderma Sa | Ivermectin enthaltende creme |
FR2867684B1 (fr) * | 2004-03-18 | 2006-05-05 | Galderma Sa | Gel creme contenant de l'ivermectine |
FR2883181B1 (fr) | 2005-03-17 | 2007-05-18 | Galderma Sa | Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee |
FR2891460B1 (fr) | 2005-09-30 | 2010-07-30 | Galderma Sa | Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum. |
EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
FR2906467B1 (fr) * | 2006-09-28 | 2012-11-09 | Galderma Sa | Utilisation de composes de la famille des milbemycines pour le traitement de desordres dermatologiques chez l'homme |
FR2907012B1 (fr) | 2006-10-12 | 2012-09-21 | Galderma Sa | Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation |
JP2011512164A (ja) * | 2007-02-20 | 2011-04-21 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 皮膚内への治療物質の送達方法 |
JP2012513387A (ja) * | 2008-12-23 | 2012-06-14 | ガルデルマ・ソシエテ・アノニム | 感水性の活性成分を含む、局所用医薬組成物 |
FR2942138A1 (fr) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | Association de composes pour le traitement ou la prevention des affections dermatologiques |
US8897218B2 (en) | 2010-10-18 | 2014-11-25 | Verizon Patent And Licensing Inc. | Femtocell location encoding |
WO2014017319A1 (ja) * | 2012-07-26 | 2014-01-30 | 国立大学法人 京都大学 | フィラグリン産生促進剤、フィラグリン産生低下に伴う疾患治療剤及び当該治療剤のスクリーニング方法 |
US9233118B2 (en) | 2013-07-08 | 2016-01-12 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
-
2014
- 2014-11-28 RU RU2016125752A patent/RU2669942C1/ru active IP Right Revival
- 2014-11-28 KR KR1020167016533A patent/KR102341441B1/ko active IP Right Grant
- 2014-11-28 EP EP14809609.2A patent/EP3074021B1/en active Active
- 2014-11-28 CN CN201480065423.XA patent/CN105916511A/zh active Pending
- 2014-11-28 AU AU2014356444A patent/AU2014356444B2/en not_active Ceased
- 2014-11-28 WO PCT/EP2014/075927 patent/WO2015079016A1/en active Application Filing
- 2014-11-28 JP JP2016535011A patent/JP6448641B2/ja not_active Expired - Fee Related
- 2014-11-28 US US15/100,302 patent/US20170000812A1/en not_active Abandoned
- 2014-11-28 CA CA2930909A patent/CA2930909A1/en not_active Abandoned
- 2014-11-28 MX MX2016006927A patent/MX370957B/es active IP Right Grant
-
2017
- 2017-07-12 US US15/648,055 patent/US10398720B2/en active Active
-
2018
- 2018-11-28 JP JP2018222176A patent/JP6667602B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN105916511A (zh) | 2016-08-31 |
US10398720B2 (en) | 2019-09-03 |
JP6448641B2 (ja) | 2019-01-09 |
JP2016538311A (ja) | 2016-12-08 |
KR20160082254A (ko) | 2016-07-08 |
RU2669942C1 (ru) | 2018-10-17 |
RU2016125752A (ru) | 2018-01-09 |
RU2018135676A (ru) | 2018-11-19 |
AU2014356444B2 (en) | 2019-11-21 |
RU2018135676A3 (es) | 2022-02-09 |
US20170000812A1 (en) | 2017-01-05 |
CA2930909A1 (en) | 2015-06-04 |
EP3074021A1 (en) | 2016-10-05 |
US20170304340A1 (en) | 2017-10-26 |
JP2019031572A (ja) | 2019-02-28 |
MX2016006927A (es) | 2016-10-28 |
JP6667602B2 (ja) | 2020-03-18 |
AU2014356444A1 (en) | 2016-06-09 |
WO2015079016A1 (en) | 2015-06-04 |
EP3074021B1 (en) | 2021-05-12 |
KR102341441B1 (ko) | 2021-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018256591A1 (en) | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | |
PH12015502261A1 (en) | Macrocyclic deaza-purinones for the treatment of viral infections | |
PH12015501648B1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
CA2956871C (en) | Compounds active towards bromodomains | |
PH12016500953A1 (en) | Tricyclic compounds as anticancer agents | |
PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
MX366899B (es) | Nuevos compuestos. | |
PH12016500978A1 (en) | Piperazine derivatives having multimodal activity against pain | |
MX2016006604A (es) | Derivados de piperidina con actividad multimodal contra el dolor. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
MX2016006927A (es) | Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevencion de la dermatitis atopica. | |
PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
NZ717880A (en) | Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors | |
MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. | |
MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
IN2013CH02437A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |